Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety of upadacitinib in Chinese inflammatory bowel disease
ChiCTR2400090481Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Adverse events, Medication status and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on ChiCTR2400090481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090481.